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Idiopathic pulmonary fibrosis is progressive, fatal lung disease with unclear 
mechanistic etiology and a dearth of treatment options. Transcriptional profiling has 
served a valuable tool in understanding the underlying perturbations in the lung 
tissues of patients and disease model systems, however whole tissue profiling 
obscures both the contribution of individual cells types in the diseased tissue as well 
as the contribution of non-fibrotic tissue surrounding the diseased tissue. The 
averaging effect confounds the ability to extract a strong disease signal and 
understand the cell-of-origin. Single-cell techniques have recently emerged that 
allow profiling of the transcriptomes of individual cells. In this work, we employ two 
state-of-the-art single cell RNA-seq techniques to IPF-relevant disease systems to 
understand cell specific contributions. In one set of experiments, we extracted and 
dissociated lung tissue from Tgfβ1 induced, as well as bleomycin injured mice 
systems. Single cells were isolated into individual wells using the Fluidigm C1 Auto 
Prep Array IFC system and single cell libraries were generated and sequenced. We 
observed the upregulation of fibroblast specific genes in cells with epithelial cell 
markers reinforcing theories of epidermal to mesenchymal transition.  In another set 
of experiments, we used a high-throughput, droplet-based system to study the 
knockdown of FENDRR, a novel long-non coding RNA (lncRNA) implicated in lung 
fibrosis in normal human lung fibroblasts (NHLFs). Here we observed cell-specific 
upregulation of genes associated with fibrosis and quiescence, as well as a 
stochastic effects demonstrating cell-cycling that would have otherwise been 
indiscernible without single-cell methods. In this work, we also address the 
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significant challenges in creating robust single cell libraries using both human and 
mouse tissue. These challenges, shortcomings, and future opportunities for single-
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1) Idiopathic Pulmonary Fibrosis Background 
Idiopathic fibrosis is a chronic, progressive, lethal, interstitial lung disease. 
The disease incidence is conservatively estimated at 3 to 9 cases per 100,000(1), 
and thus it is relatively rare, but within certain age groups, the disease is more lethal 
than a diagnosis of lung cancer. 
The core process at play in this disease is the accumulation of fibrotic lesions 
in the lung that replace the normal lung parenchyma(2). This results in both a 
restriction in respiration due to the increased stiffness within the lung, as well as a 
loss of diffusion capacity due to both loss of normal lung parenchyma as well as the 
increased separation between capillaries and the inner compartment of the alveoli. 
Forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) are 
thus the standard staging and progression criteria(3). In the normal progression of 
the disease, patient lung function declines steadily, and patients are prone to lung 
infections causing step-function like declines in FVC and DLCO(3, 4). Loss of these 
physiologic parameters is thus the mechanism of death for these patients. 
Complications of the disease include pulmonary hypertension, thromboembolic 
disease, and lung cancer(5). Most of these are thought to be secondary to the 
fibrotic process, but as disease etiology is unclear, these complications may have 
contributions from the primary etiology or etiologies. 
Histopathology 
Classically, the histologic diagnosis of IPF is based on the pattern of usual 
interstitial pneumonia (UIP)(6).  While current classification relies on integration of 
 7 
histologic, radiologic and clinical criteria, the underlying pathologic changes are still 
understood histologically. UIP is marked by fibrotic regions potentially positive for 
honeycombing in subpleural and paraseptal regions (6) as seen in Figure 1.A and 
1.B(7). The location specific differences in the disease are a critical differentiating 
factor with normal tissue seen adjacent to established disease. Immature hyaluronic 
acid rich matrix secreted by fibroblastic foci (Figure 1.C) is present near recently 
generated scars and is bound by areas of significant epithelial cell damage and 
death(6, 8). This process causes a regeneration response and proliferation of 
alveolar type II cells(9). Thus there is heterogeneity both from a temporal 
perspective with active disease in some regions and mature scar in others, as well 
as spatial differences in the extent of tissue injury seen(6). Notably, there is an 
typically an absence of necrotic debris and inflammatory cell infiltrate(10). 
Figure 1: A. High-resolution CT scan of 
IPF lung demonstrating pervasive 
honeycomb cysts (yellow arrows) in the 
subpleural region (red arrow) (Image 
courtesy of Naftali Kaminski).  B. Computer 
reconstruction of the fibrotic reticulum  
(Pleura – Yellow. Blood vessels – Red. 







IPF pathogenesis remains unclear but the disease is thought to occur due to 
recurrent injury to the alveolar epithelium and is perpetuated by an abnormal repair 
process resulting in fibrosis that extends from the epithelium to the interstitium(8). 
The injury is thought to alter the basement membrane and permits entry of 
mesenchymal cells(11) causing a complex interplay of cytokines, basement 
membrane driven cellular changes, and non-classical inflammation resulting in 
highly active, contractile fibroblasts(12).  
These activated fibroblasts and an emerging population of myofibroblasts 
organize to form fibrotic foci (Figure 1.A) that are precursors to end-stage fibrosis(7). 
These foci develop near locations of epithelial injury and basement membrane 
disruption. The persistence of these foci may be due to inhibition of normal apoptotic 
processes as well as initiation of senescence. Targeting this senescence process 
has been shown to reverse fibrosis that accumulates due to oxidative injury in aging 
mice(13).  
Centrality of Tgfβ1 
Transforming growth factor beta 1 (Tgfβ1) is a highly conserved, and 
ubiquitously expressed cytokine important in tissue growth, injury, and repair across 
many disease categories including cancer, inflammation, and fibrosis(14). It plays a 
central role in IPF pathogenesis in multiple lines of investigation. It is increased in 
tissue samples from patients with IPF(15) as well as in tissue in animal models of 
the disease(16). Animal models also demonstrate that overexpressing active Tgfβ1 
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leads to lung fibrosis(17) and blocking the Tgfβ1 receptor I (ALK5) (18)and it’s down 
stream signaling pathways significantly reduces or prevents fibrosis (18, 19). 
 Tgfβ1 signaling occurs through the interaction of active Tgfβ1 with the  Tgfβ1 
receptors I and II on target cells(20, 21).  As  Tgfβ1 is synthesized and held in an 
inactive form in a latent complex, it must be activated. It can be activated though a 
number of processes including physical changes in parameters like pH; extreme 
temperature changes; enzymatic cleavage via a number of proteases including 
plasmin, tryptase, and MMP-2 and -9; as well through interactions with integrins(22). 
The integrin activation has received special attention as integrins allow for direct 
communication and integration of extracellular and intracellular signals to the 
external environment(23). In this case, the avB6 integrin has been implicated in 
initiating and perpetuating fibrosis in various murine models(24). Moreover, blocking 
certain integrin signaling, such as avB1 and avB6, has been shown to ameliorate or 
prevent fibrosis(25, 26).  
Activated  Tgfβ1 stimulates fibroblasts to transdifferentiate into myofibroblasts 
and induces epithelial to mesenchymal transition in epithelial cells. Tgfβ1 is also a 
potent inducer of extracellular matrix deposition(27).  
Relevance of single cell methods 
Because of the extreme heterogeneity of cell types in the lung and the spatial 
and temporal variability in disease, tissue level measurements of gene expression 
are likely to obscure specific signals of disease that provide greater insight on 
disease etiology or mechanism(28).  
 10 
The progressive nature of IPF, the complex interplay of cytokines, and the 
emergence of transdifferentiated cell types points to a key need for single-cell 
analysis. For example, the close proximity of mesenchymal cells to epithelial cells 
may contribute to the regulation of cell proliferation and connective tissue synthesis 
by fibrogenic cytokines released from epithelial cells. The current hypothesis 
suggests that repeated subclinical injury to the lung injures the alveolar epithelial, 
the subepithelial, and adjacent endothelial basement membranes(9). This injury 
permits entry into the alveoli of cells of the mesenchymal lineage, thus resulting in a 
mixed population even within a rather discrete a well-defined cellular niche.   
Moreover, there is known to be heterogeneity in collagen expression from the 
fibroblast population indicating a potential underlying phenotypic difference. In situ 
hybridization experiments have demonstrated that fibroblastic foci specifically 
showed an increase in expression of type I procollagen mRNA which was not 
observed in other areas(29).  
Cell populations also shift within IPF lungs. Microscopic characterization of 
normal lungs indicate that 8% of cells are AT1, 16% are AT2, and cells in the 
interstitial space are 37% of the total cell number with a subset of these of being 
fibroblasts(30). Given the fibrotic changes that occur in the lung, including the 
development of the histological hallmark fibroblastic foci occurring at sites of putative 
epithelial injury, there is an expansion of the fibroblast population in IPF lungs, 
however the source and exact quantification changes in cell number is not well 
described(31, 32).  
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Given the importance of the fibroblast in the proliferation of IPF, 
characterizing the phenotypes and underlying expression differences between the 
normal appearing fibroblasts that reside in the normal regions of the IPF lung relative 
to both the normal appearing fibroblasts in diseased areas as well as the diseased 
fibroblasts in fibrotic foci will provide important clue regarding intermediate disease 
states and disease progression and diversity within an individual.  
Cell types of interest in the fibrotic process 
Type I and II Alveolar epithelial cells 
Alveoli are lined by squamous type 1 alveolar epithelial cells (AT1) and 
cuboidal type 2 alveolar epithelial cells (AT2)(33). AT1 cells serve as the primary 
cells across which gas exchange occurs(34). Their flat shape facilitates the rapid 
diffusion of gas and they are characterized by expression of Hopx, podoplanin 
(Pdpn/T1alpha), and AGER)(35). AT2 are considered a stem cell that will 
differentiate into AT1s and clonally expand to replenish AT2s in situations of lung 
injury(36). Additionally, AT2s serve as secretors of surfactant and are marked by 
expression of SftpA-C and LysM(35, 37). 
In IPF, AT2s proliferate in response to injury but do not normally re-
epithelialize the alveolar space(38, 39), potentially due to persisting abnormalities 
such as fragmentation of alveolar basement membrane components such as 
hyaluronic acid(40, 41). In fact, both epithelial injury and basement membrane injury 
appear necessary for the development of interstitial fibrosis. Abnormalities in the 
alveolar basement membrane provide the impetus for migration of mesenchymal 
cells into the alveolar spaces, followed by deposition of collagen preventing the 
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expansion of a collapsed airspace(42).  The perpetuation of this process by chronic 
injury results in a continuing process of fibrosis and remodeling. Recent single cell 
work in isolated epithelial cells from normal and diseased lung has shown that in 
disease three subsets of epithelial cells exist all of which show abnormal 
differentiation. These cells frequently co-express markers of AT1 and AT2 cells, as 
well as conducting airway specific markers. These cells are not thought to be related 
to normal undifferentiated lung progenitor cells, and instead likely represent a failure 
to suppress multilineage differentiation programs(43).    
Fibroblasts 
Fibroblasts comprise a large component of the stromal population of the lung 
parenchyma along with myofibroblasts, pericytes, and lipofibroblasts. They primarily 
secrete and degrade collagen in a tightly regulated process to preserve the normal 
lung structure. They secrete both type I and type II collagens and serve to break 
down up to 40% of newly synthesized collagen(44, 45).  
In IPF, the population of collagen secreting fibroblasts is thought to be 
increased especially within fibrotic foci(7, 42, 46). These fibroblasts lie on the 
alveolar side of the injured airspace as evidenced by detection of residual areas of 
basal lamina(47). Fibroblasts isolated from lungs with early fibrosis show much 
greater replicative potential than fibroblasts from normal lungs, or those from lungs 
with late stage fibrosis(48). Moreover, late stage fibroblasts from IPF lungs also 
demonstrate an increased senescent associated phenotype as determined by 
resistance to oxidative stress(49). Thus the phenotype of fibroblasts appears to 
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progress through two stages, initially characterized by increased proliferation in 
response to injury, and later by lack of apoptosis and cellular senescence.  
Myofibroblasts 
Myofibroblasts express both features of fibroblasts as well as smooth muscle 
cells and are marked by expression of alpha-smooth muscle actin (SMA) expressed 
by the gene ACTA2(50). Notably, they produce collagen at higher levels than normal 
fibroblasts(51). In IPF, myofibroblasts emerge from the differentiation of fibroblasts in 
response to Tgfβ1, as well as other cytokines(40).  Epithelial mesenchymal 
transition, driven by growth factors and transcription factors, is thought to be another 
source for IPF myofibroblasts(52, 53).  Tgfβ1, epidermal growth factor (EGF), 
hepatocyte growth factor (HGF), and fibroblast growth factor (FGF) can cause 
epithelial cells to acquire myofibroblast markers including SMA, FSP1 and lose 
epithelial markers including E-cadherin and ZO-1(53).  
Myofibroblasts from IPF lungs also show microRNA abnormalities relative to 
normal lungs including increased levels of mIR-21 and decreased expression of 
mIR-29. mIR-21 promotes proliferation and differentiation and mIR-29 inhibits 
synthesis of fibrogenic proteins(54). As microRNAs regulate global transcriptional 
process, IPF myofibroblasts represent a population of cells with widespread 
dysfunctions in protein expression potentially at the post-transcriptional level.  
2) Model systems for IPF 
Bleomycin induced lung injury model 
The bleomycin mouse injury model involves intratracheal administration of a 
single dose of bleomycin. Bleomycin was previously used to treat cancer but quickly 
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fell out of favor as it was found to cause pulmonary fibrosis as a side effect of its 
chemotherapeutic purpose in certain populations. This was found to be due to low 
levels of the hydrolyzing enzyme for bleomycin, bleomycin hydrolase in the lungs of 
certain individuals. The injury from bleomycin occurs due to a combination of direct 
DNA strand breakage, free radical generation, and induction of oxidative stress.(55)  
The intratracheal instillation of bleomycin causes injury to alveolar epithelium 
proceeded by a wave of activated macrophages and neutrophil-rich inflammatory 
infiltrate that resolves in one to three weeks(56-58). After the initial inflammation is 
cleared, fibroblast proliferation is noted and significant ECM is deposited. The fibrotic 
response in this model can be seen biochemically and histologically by day 14 with 
maximal responses at days 21-28. (57). In this process, myofibroblasts and 
fibroblast both increase, but while fibroblast number return to base line values after 
four weeks, myofibroblast quantities are 10-fold higher than in the normal lung(59), 
leading to potentially persistent production of ECM(60). Another study demonstrated 
development of two distinct mesenchymal cell populations one located in areas of 
active fibrosis and positive for SMA, desmin, and procollagen, and the other located 
in submesothelial areas and expressing only SMA and procollagen(61).  
 Tgfβ1 overexpression model 
As Tgfβ1 is thought to play a major role in the development of IPF, model 
systems have been developed that overexpress Tgfβ1 in a lung specific fashion in 
order to understand the specific impact of this model system(17). A triple transgenic 
mouse was developed to express biologically active Tgfβ1 in a tightly inducible 
fashion. Induction of Tgfβ1 in this model caused transient apoptosis of epithelial 
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cells, followed by inflammation rich in mononuclear cells, parenchymal and 
interstitial fibrosis, myofibroblast hyperplasia, and eventual alveolar septal rupture 
and honeycombing. An important feature of these mice was the reversibility of the 
fibrotic process. Withdrawal of the doxycycline stimulus inducing Tgfβ1 production 
resulted in resolution of fibrosis and normalization of collagen content in the affected 
lung after only one month. The investigators further characterized the mechanism of 
fibrosis in this model focusing on the initial event of epithelial apoptosis. Apoptosis 
was inhibited using a variety of strategies, and was found to be a necessary 
condition for the Tgfβ1 induced fibrotic response 
Other model systems for IPF 
Multiple model systems for IPF exist outside of the bleomycin instillation and 
Tgfβ1 overexpression models described above. Several of these models involve 
delivery of an injurious chemical or energetic stimulus. Instillation of FITC, a 
fluorescent molecule, causes fibrosis that is dependent on CCR2 signaling recruiting 
fibrocytes(62) and production of IL-13(63). The advantage of this model is that 
fibrosis can be localized with by immunofluorescence imaging for green color of 
FITC(64) and response is persistent for at least six months(65). Irradiation at a dose 
of 12-15 Gy can also induce fibrosis, but does so dependent on the mouse strain 
with C57Bl/6 mice being the most fibrosis prone. The fibrosis is thought to be 
induced by an interplay of TNF-a and Tgfβ1 signaling depending on the mouse 
strain(66). Thus the advantage to this model system is that it allows investigations 
into genetic causes of fibrosis, but requires housing mice for at least the 20-24 
weeks it takes for fibrosis to develop(67). Silica instillation is another option for 
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inducing fibrosis. This system has advantages of also being strain dependent (68) 
facilitating genetic understanding of silica-induced fibrosis, and as silica is not 
cleared from the lung, the fibrotic stimulus is persistent(69).  
Other transgenic models have been developed to induce overexpression of pro-
fibrotic stimuli such as GM-CSF, TNF-a, and IL-1B(70). These have been delivered 
via AAV allowing for transient expression, but somatic and germline lentiviral-
mediated incorporation of fibrotic transgenes  has also been demonstrated.   
3) FEDNRR, a novel lncRNA plays a role in cell senescence  
FENDRR is a lung-specific long non-coding RNA (lncRNA). LncRNA are a type 
of regulatory RNA that play a prominent role in development, differentiation, and 
epigenetic modification. Aberrant lncRNA expression has been implicated a number 
of human diseases, but has not been well characterized in the complex process of 
pulmonary fibrosis(71). FENDRR’s role in cellular senescence in normal human lung 
fibroblasts was first characterized in our lab. FENDRR was selected based on a 
high-throughput microarray screen of lincRNA expression across 400 lung samples 
in patients with COPD and various forms of interstitial lung disease(72). FENDRR 
was found to be the most downregulated lincRNA in IPF lungs, and was validated 
using the nCounter assay (results under publication). FENDRR knockdown in NHLF 
showed a prominent role for induction of cellular senescence as well as 
myofibroblastic differentiation. Mechanistic studies showed that loss of FENDRR 
results in epigenetic remodeling through the PRC2 complex and alters methylation 
on the p16 and GATA6 promoters to activate downstream expression of senescence 
associated genes(73). Aging has been shown to play a key risk factor in the 
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development of IPF and FENDRR points to a specific epigenetic mechanism by 
which cellular senescence is regulated in fibroblasts. 
4) Single Cell Methods 
C1 
The C1 is an instrument designed by Fluidigm corporation to enable 
automation and reproducibility in single cell genomic experiments(74). The 
instrument, and associated chips isolate single cells into microliter wells and 
precisely deliver reagents into those wells. These reagents can be specific to the 
protocol at hand, and at the moment protocols exist for high-throughput sequencing 
of cellular mRNA, miRNA, methylation changes, chromatin marks, and other 
genomic signatures(75).  
 
Figure 2: Key features of the C1. A. A typical IFC is shown here. Reagents and cells are 
loaded at pre-determined locations and reaction products are harvested from specific well 
locations. B. Demonstrates the SMART-seq protocol for amplification of cellular RNA using 
oligo-dT capture and template switching. Captured RNA (dark blue) with polyA tail (red) is 
primed for first strand synthesis by an oligo-dT sequence primer (yellow) with a common PCR 
handle on the 5’ end (green). First strand extension adds untemplated dTs. A template switching 
primer with 3’ ribosylated guanosine bases and a 5’ common PCR handle is used to create the 
second strand of DNA using the ‘first strand’ as a template. The common PCR handles can now 
be used to amplify the newly derived cDNA. 
Oligo-dT capture 
RT – First strand synthesis 
Template switching 
Extension via PCR 
A B 
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The instrument operates on a proprietary microfluidics technology that 
automatically flows a cell suspension through a complex array of gates, detects the 
presence of a single entering cells through voltage sensitive gates, captures that 
cell, and diverts the remaining cell suspension to the next well . An example chip is 
shown in Figure 2.A. The chip can then be physically inspected under a microscope 
to confirm capture of single cells, or alternatively to note the presence of empty wells 
or cell doublets. Reagents can also be added to stain the cells to determine cell 
viability. 
For the mRNA-seq system employed to analyze single cells in this paper, the 
procedure utilizes the SMARTer template switching reaction(76). Briefly, a lysis 
reagent lyses the cells and stabilizes the liberated RNA, after which an oligo-dT 
capture and priming method is used to prime first strand synthesis of cDNA (Figure 
2.B). The specialized reverse transcriptase adds non-templated dC nucleotides to 
the terminal 3’ end of the nascent strand.  A template switching primer with a 
common PCR tag on the 5’ side and dG nucleotides on the 3’ side is used to prime 
this first strand and confer a common PCR tag. PCR is then used to amplify and 
enrich these properly captured sequences. Enriched cDNA is then moved into a 96-
well plate where Illlumina Nextera library preparation occurs. Each sample is given a 
well-specific barcode by addition of unique PCR primers during this process and 
then the 96 wells are pooled for final preparation for sequencing and sequencing. 
The barcodes are then used to demultiplex the sequencing results and data 
processing pipeline is used to determine the abundance of expressed genes in each 
cell. Subsequently, low quality cells and wells containing cells known to be doublets 
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or empty wells are filtered out, reads are aligned to a known genome, and counted 
using one of several quantification methods. 
Drop-Seq  
Drop-Seq was published in 2015 and functions by co-encapsulating single 
cells and barcoded beads into nanoliter droplets(77). At the time it was released it 
increased throughput 50-100 fold and reduced the per-cell cost single cell library 
assembly by over 100 times relative to the C1. The clear advantages of this system 
provided a  compelling reason for our lab to move forward with implementing this 
technology. 
 The Drop-Seq platform leverages several advances in microfluidics, high 
throughput sequencing, microparticle chemistry, and barcode-based molecular 
biology. A reproduced image demonstrating the main feature of the system is shown 
in Figure 3(77). The system is assembled from commercially available equipment 
and reagents. Three syringe pumps, holding a cell suspension, barcoded beads, and 
oil, with the former two in an aqueous suspension, are simultaneously flowed into a 
microfluidic chip (Figure 4). The beads are synthesized such that each bead is 
decorated with a millions of barcoded primer sequences, which are identical on a 
given bead, but distinct from every other bead (Figure 3.B, 3.C). A nozzle at the flow 
junction of the aqueous solution and oil solution results in surface tension forces that 
causes formation of droplets at the rate of approximately 80,000 per second (Figure 
4.C)(77). 
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Beads and cells are encapsulated randomly, subject to Poisson probability 
Figure 3: Overview of the Drop-Seq Protocol. A. Cells and beads are combined in a microfluidic device 
to co-encapsulate beads and cells. Lysed cells are then subject to reverse transcription to allow cellular 
polyA-RNA to inherit unique barcodes from beads. Libraries are generated from this first strand of DNA 
and sequenced using paired end sequencing. B. Beads are designed with three regions containing a 
common PCR handle, a cell barcode region, and a UMI. C. The diversity of cell barcodes and UMIs is 
generated using 12 rounds of a split-pool synthesis design for the cell barcode and 8 round of random 
addition for the UMI. D. Paired-end reads are computationally de-multiplexed by grouping reads with the 
same cell barcode to one cell. Reads are subsequently collapsed by UMI to control for amplification 




distributions (Figure 5). In order to achieve droplets where only one cell and one 
bead end up in a droplet, a dilute cell and bead suspension must be created so that 
on average, less than one cell or bead becomes encapsulated into a droplet. Thus, 
most droplets formed are empty (Figure 4.D) and a small number contain a bead or 
a cell, and an even smaller number contain both a bead and a cell. This results in 
only a small fraction of the total number of cells flowed in becoming successfully 
A B 
C D 
Figure 4: Drop-Seq Setup Photos. A. Overall set up Drop-Seq Rig. Three 
syringe pumps with oil, cells, and beads feed into a microfluidic chip shown in B. 
C. Microfluidic channels visualized under a microscope at 10x magnification. D. 
Droplets formed under a microscope. Rare droplets receive a bead and a smaller 
fraction also contain a co-encapsulated cell.  
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sampled. Despite this limitation, the large number of total cells are sampled thus 
resulting in a representative view of the whole population(77).  
The bead solution contains a lysis reagent which, shortly after mixing with the 
cell solution, causes breakage of the cell membrane within the encapsulated droplet 
releasing the contents of the cell including the mRNA. Polyadenylated mRNA binds 
to a ‘poly-T’ sequence on the beads. The droplets are captured in a Falcon tube as 
oil-water emulsion and all further processing occurs in bulk for a given sample. In the 
next step, the droplets are broken releasing the mRNA coated beads (termed 
STAMPs – “single-cell transcriptomes attached to microparticles”), washed, and 
incubated with a reverse transcriptase. This droplet breakage step also releases 
significant ambient RNA from cells that did not associate with a bead as well as 
beads that did not co-encapsulate with a cell. This necessitates very quick 
preparation and several washing steps to eliminate this unbound mRNA to minimize 
the technical noise. During the reverse transcription step, transcripts bound to a 
bead are extended, primed by the unique barcode on the bead. Next, an 
endonuclease digests unused primer sites and the cDNA is PCR amplified. The 
sample is analyzed using a BioAnalyzer to inspect the size distribution and 
amplification extent of the cDNA pool. This pool is then prepared for sequencing 
using a ‘tagmentation’ process and samples are sequenced using paired-end 
sequencing on an Illumina sequencer. The first read reads off the special Drop-Seq 
barcode, and the second read provides the sequence of the 5’ end of the original 
transcript. This is known as 5’ tag counting, which is discussed in the Amplification 
Bias section(78).  
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Sequencing results are then processed using software provided by the Drop-
Seq authors to demultiplex, map, and count the transcripts. Briefly, the process 
involves extracting out the barcode portions of the read, trimming primer sequences, 
aligning the reads to a reference genome, selecting true STAMP barcodes, and 
creating a digital gene expression (DGE) matrix. The DGE generation process uses 
both the cell and the UMI components of the barcode. The cell barcode is used to 
demultiplex cells while the UMI to control for amplification bias during the multiple 
amplification steps.  
 As opposed to the C1 system where the C1 chip can be visually inspected for 
cells doubling up in a well, in Drop-Seq there is no way to physically inspect droplets 
as cells as lysed shortly after creation of the droplets. Thus, the protocol is validated 
by conducting a species mixing experiment. In the species mixing experiment, a 
50:50 suspension of mouse 3T3 cells, and human HEK293T cells is flowed through 
the system. Sequencing results are demultiplexed and transcripts are counted for 
Figure 5: Diagram of Poisson probability distributions : Beads are encapsulated at very low 
values of µ ~ 0.1 such that on average less than 1/10 cells receives a bead. This ensures that 
the rate of doublets or more, i.e. events per sample > 1, where an event represents 
encapsulation, is very close to zero.   
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each bead. As the counting tags each read with a cell barcode, cell barcodes are 
inspected to determine the percentage of transcripts that align to the mouse genome 
versus the human genome. Ideally, cell barcodes should be associated with only 
mouse transcripts, or only human transcripts. However, by chance, sometimes two 
cells will enter a droplet together and in the event that it is a human cell and a mouse 
cell, the system will be able to easily detect this occurrence. The frequency of these 
occurrences provides an estimate of how often two cells of any type are co-
encapsulated, and thus how robust the system is at generating true single cell 
droplets. In a successful experiment given standard cell loading concentrations, 
fewer than 5% of STAMPs should contain both human and mouse transcripts(77).  
Comparison of Single Cell Methods and shortcomings 
The C1 and Drop-Seq provided powerful methods for reproducible, 
multiplexed RNA-sequencing analysis, yet each has its own strengths and weakness 
that must be considered.  
The C1 is inherently lower throughput than Drop-Seq, as the commercially 
available chips at the time of experimentation could capture a maximum of 96 cells 
with single cell capture rates close to 70%, resulting in typical capture of 
approximately 70 cells(28). This becomes most significant from a cost and timing 
perspective as the cost for capture of a single cell on the C1 system is approximately 
$3.50 whereas for Drop-Seq it is $0.10 depending on the cell density and acceptable 
doublet rate(77). From a timing perspective, a typical Drop-Seq run captures 
between 200 to 2,000 STAMPs in a 15-minute interval. An hour of runtime can thus 
produce up to 8,000 STAMPs in the same amount of time as it takes to run the 
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capture step on the C1(28, 77, 79). On Drop-Seq, however significant personnel 
time and expertise is required to process the samples after collection of the droplet 
emulsion which can introduce significant technical variability as many of the steps 
need to be performed quickly and carefully. The C1, on the other hand, requires 
much less hands-on time and the protocol is less technically demanding.  
The C1 has the distinct advantage of being able to visualize captured cells in 
the well before they are lysed. This allows for determination of wells containing true 
cell doublets, or empty wells. However, this visual identification was found to be 
faulty in several models of chips by Fluidigm after a species mixing experiment 
revealed significant doublet populations on visually confirmed single cells(77). 
Fluidigm determined this was a flaw in their well design that allowed two cells to sit 
on top of one another in a way that prevented discriminating individual cells(80).  
While the species-mixing experiment confirms the overall viability of Drop-Seq 
for generating single cell libraries, it provides no guarantees for doublet formation in 
subsequent experiments. Notably, in experiments involving digestion of tissues, 
incomplete digestion of cell-cell proteins can result in significant doublet artifact with 
potentially minimal ability to detect these doublet populations. Visual identification of 
cells does not, however, eliminate the issue of ambient RNA contamination of results 
which is a significant problem for all single cell sequencing protocols, especially for 
sequencing of tissue samples as they all involve generation of a cell suspension.  
“Amplification bias” refers to the technical variability introduced by PCR 
amplification of transcripts due to their size, GC-content, and potential secondary 
structure(81). In the cause of transcriptional analysis, this causes certain transcripts 
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to be more easily amplified during cycles of PCR relative to others, and because the 
process results in exponential amplification, two transcripts present in relatively 
equal abundance, may be amplified such that one is orders of magnitude greater 
abundance than the other.  
Unique molecular identifier (UMI)-counting was first used by Kivoja et al to 
address general amplification bias(82), and then later applied directly to single-cell 
RNA-seq by Islam et al.(78)  Amplification bias is especially significant in single cell 
samples where significant amplification cycles are required to bring the small 
quantities of RNA in a single cell into the detectable range. A UMI strategy for single-
cell sequencing requires presence during RT of a randomly barcoded primer 
consisting of 5-8 bases resulting in 1,024 – 65,536 unique barcodes, depending on 
the length. These barcodes are inherited during first-strand synthesis of cDNA and 
are maintained during all cycles of amplification. During paired-end sequencing, the 
UMI barcodes of all the transcripts are read from one end, and the gene identity is 
read from the other end. It is assumed that all detections of a gene-UMI combination 
resulted from amplification of one original molecule of mRNA. Thus, detected events 
of a gene-UMI combination are collapsed to a count of one.  In the case of Drop-
Seq, a set of reads with identical cell barcode-gene-UMI reads are collapsed to an 
expression value of one for that gene in that cell barcode. Introduction of UMIs has 
been shown to significantly reduce the technical variability and increase 
reproducibility in single cell experiments relative to simply counting reads(78). The 
trade-off is that the 5’ end of the original mRNA molecule most distal to the polyA 
priming site is lost and thus only the 3’ end of a molecule is detected. This limits the 
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ability to detect mutations, allele specific transcripts, and alternative splicing that 
occurs at the 5’ end of the mRNA.  
Drop-Seq implements both cell barcoding and UMI counting, thus allowing for 
correction of amplification bias. The C1 protocol used in this paper does not use UMI 
counting, and thus allows for sequencing of the full transcript, but the data do suffer 
from noise introduced by amplification.  
The newest platform for single cell RNA-sequencing is known as the 
Chromium 10x system. The system is akin to the Drop-Seq in that it uses barcoded 
beads to capture cells in nanoliter droplets. The advantages to this system are lack 
of plug-and-play operation and significantly improved cell capture. The system does 
not require assembly as the Drop-Seq rig does and the RT process happens inside 
of the droplet obviating a major ambient RNA contamination concern. The Chromium 
system also captures approximately 50% of the input cells because there is no 
possibility for bead doublets and thus the system only needs to operate at Poisson-
limiting cell quantities. Despite these advantages, the device and consumable 
remain quite expensive such that the per cell isolation cost is still approximately an 
order of magnitude higher than Drop-Seq.  
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Statement of Purpose 
The purpose of this line of research was to discover heterogeneity of well-studied 
models of IPF on a single-cell basis.  
Specifically our goals were to: 
1. Analyze the shift in cell populations and their expression profiles using 
multiple in vivo models of fibrosis on the C1 
a. Bleomycin mouse model 
b. Tgfβ1 induced fibrosis model 
2. Use Drop-Seq to determine the heterogeneity of response to FENDRR 
knockdown on a single cell method, as well as to determine the usefulness of 
Drop-Seq for future experiments.  
We hypothesized that in our mouse models, we would see a significant 
upregulation of apoptotic and fibrotic markers in bleomycin treated and Tgfβ1 
induced mice in a single cell specific manner. Specifically, we expected to see single 
cells that demonstrated an expansion in the number of inflammatory cells, fibroblasts 
and myofibroblasts, and potential transitional phenotypes.  
In the FENDRR knockdown experiment, we expected to see each cell 
demonstrate a clear discrimination of response to siRNA treatment. We also 
hypothesized there may be some population heterogeneity of both samples that we 
would be able to detect due to differences in the cell cycle state of the cells. Finally, 
given the importance of FENDRR as a regulator of cell cycle state, there may be 
distinct changes in the impact of FENDRR knockdown depending on the state of the 
cell during FENDRR treatment.  
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Overall these experiments provide internal validation for future use of these cutting-




1) Generation of model mouse systems 
Doxycycline-inducible Tgfβ1 transgenic mice. The triple transgenic CC10-rtTA-tTS- 
Tgfβ1 (hereby referred to as  Tgfβ1+) mice were previously generated by the Elias 
Lab(17) and key details are summarized here. Three transgenes were knocked-in to 
C57BL/6 mice using pronuclear injection and characterization of the progeny. The 
first construct contains the lung-specific CC10 promoter and a tetracycline inducible 
Tet-O operon activator (rtTA). The second contains the tet-O operator, a minimal 
CMV promoter, and a modified  Tgfβ1 cDNA. Crucially, the  Tgfβ1 is modified 
substituting serine codons for cysteine at positions 223 and 225 preventing latency 
associated protein-binding, and thus fully active  Tgfβ1. The third construct contains 
a tetracycline controlled transcriptional silencer (tTS) driven by the CC10 promoter. 
The CC10 promoter drives lung-specific production of the rtTA and rTS, the former is 
active under doxycycline, and the latter is inactive under doxycycline. The presence 
of dox liberates the rTS from the Tet-O operon and allows binding of rtTA thus 
allowing for a tightly controlled and reversible lung-specific system for the expression 
of  Tgfβ1.  
In the experiment, two female 6-8 week old Tgfβ1+ mice, one with doxycycline 
added to the water, and the other without doxycycline added, and one wild-type 
littermate was used as a control. Doxycycline was added to drinking water at a 
concentration of 0.5 mg/mL and administered from day 0 to day 7. Mice were 
sacrificed using a lethal dose of urethane and tissues harvested at day 14. 
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Bleomycin-induced lung injury mouse model. One wild-type C57BL/6 mice at 6-8 
weeks of age was given one dose of intratracheal bleomycin at an approximate dose 
of 0.5U/kg on day 0. One control mouse was treated with intratracheal PBS as a 
control. Mice were sacrificed using a lethal dose of urethane and mouse lungs were 
harvested at day 14 employing perfusion of the lung with PBS via the right ventricle.  
2) Tissue extraction and dissociation 
Extracted lungs are dissociated using the MACS automated dissociation system 
(Miltenyi) according to the manufacturer protocol. Briefly, extracted lungs were 
thoroughly washed in a PBS solution and placed in gentleMACS C tube containing a 
proprietary enzymatic digestion solution. A fast round of mechanical digestion was 
followed by slow agitation at 37C for 30 minutes, and another fast round of 
mechanical digestion. Cells were pelleted by centrifugation, re-suspended, and 
filtered twice to remove dead cells and debris.  
3) C1 based library creation 
C1 library creation was achieved according to the manufacturer manual. The 
medium size IFC chip was used as it is encompasses the expected size range of 
mouse lung cells (10-17µm). The IFC was primed by loading Harvest Reagent, 
Preloading Reagent, Blocking Reagent, and Cell Wash Buffer into specified wells on 
the IFC chip and placed into the C1 system for 12 minutes to complete the priming 
protocol. Cells obtained from tissue extraction were re-suspended in Suspension 
Reagent to a final concentration of 100/µL and 60µL was loaded onto the inlet port 
of the IFC. The IFC was placed into the C1 system for 65 minutes to run the loading 
protocol. After loading, the wells were individually inspected to determine the 
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occupancy (0, 1, 2 or debris). In the next step, Harvest Reagent, lysis mix, RT mix 
containing SMARTScribe Reverse Transcriptase (Clontech), and PCR mix 
containing the Advantage 2 Polymerase Mix (Clontech) were loaded into the 
designated inlet ports, and the IFC was placed into the C1 for the 8.5 hour process 
of lysis, reverse transcription, and harvest. Notably, the SMART-seq2(83) RT 
strategy was used and 21 cycles of amplification were used as per the standard C1 
protocol. Amplified products were transferred to a 96 well plate and a modified 
Nextera XT (Illumina) DNA library preparation protocol was carried out. Post-
amplification cDNA were quantified individually using a multiplexed Picogreen assay 
and read on a plate reader to determine the required dilution for tagmentation. 
Samples were diluted to 0.2ng/µL and incubated with tagmentation buffer that 
simultaneously fragments the full length cDNA and tags the fragmented molecules 
with a standard Illumina barcode. These fragmented molecules were then incubated 
with Illumina specific multiplexing index primers and another 12 cycles of PCR were 
carried out. The samples were pooled and AMPure XP beads (BD) used at a ratio of 
0.9:1 of pooled volume to remove primers. The final pooled library was quantified 
using a BioAnalyzer High Sensitivity DNA chip (Agilent). Sequencing was performed 
on a HiSeq 2500 (Illumina) in High Output mode.  
4) NHLF FENDRR knockdown (KO) 
siRNA targeting duplexes were designed using the web tools available from GE 
Dharmacon. The sense sequence was ‘GAAGAUACCAAGUGAAAUAUU‘ and the 
anti-sense sequence was ‘UAUUUCACUUGGUAUCUUCUU’. Manufacturer 
designed and validated non-targeting siRNA were used as a negative control. 
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Transfection of siRNA was conducted with Lipofectamine 2000 diluted in Optimem 
(Life Technologies) reduced media. After 24h cells were harvested from the plate 
and prepared for the Drop-Seq protocol.  
5) Drop-Seq based library creation 
Drop-Seq protocols were executed using the reagents, primers, and protocols 
described in the Drop-Seq 3.1 manual and paper(77). An overview of the steps of 
the protocol is provided in the introduction as an overview of the Drop-Seq protocol 
and further details about each experiment are provided below.  
Species Mixing Experiment 
Mouse 3T3 cells and human HEK 293T cells were cultured using standard 
conditions to 75% confluence and harvested by TrypLE. Cells were diluted to a final 
concentration of 100 cells/µL in and barcoded beads (Chemgenes) were suspended 
in lysis solution to a final concentration of 120 beads/µL. Cells, beads, and oil were 
loaded onto syringe pumps and flowed at a rate of 4,000, 4,000, and 15,000 µL/hr 
respectively to create a droplet in oil suspension. After droplet generation, droplets 
were broken using a 30mL solution of perflurooctanol in 6X SSC. The recovered 
beads, a subset of which were heavily enriched with the RNA of the cell they were 
encapsulated with, were washed several times with 6X SSC to remove ambient RNA 
and resuspended in a RT mix containing Maxima H- reverse transcriptase (Thermo 
Fisher). Beads were washed again and incubated with Exonuclease I (NEB) to 
remove unextended primers on the beads. The beads were washed again, counted 
on a hemocytometer, and diluted to aliquot 2,000 beads into each PCR tube. A total 
of 6,000 beads were aliquoted for 10 cycles of PCR with HiFI Hotstart Readymix 
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(KAPA Biosystems). Note that the recommended cycle number for the species 
mixing experiment is 13 cycles. PCR products were pooled and cleaned up using 
AmpureXP beads at 0.6:1 ratio and the post-clean up products were characterized 
on a BioAnalyzer HS Chip. The pooled samples were tagmented and enrichment 
PCR using special ‘P5-SMART-PCR hybrid oligo enables amplification of only 
tagmented fragments that contain the Drop-Seq barcode. 12 cycles of PCR were 
performed, and the sample is cleaned up using the 0.6x AmpureXP bead ratio and 
characterized on the BioAnalyzer HS chip. A final 10uL library pool at a 3nM 
concentration was created as the input for denaturation for running on the MiSeq 
platform. Read specification for the MiSeq were as follows: Read 1, Read 2, and 
Read 1 index lengths are 20bp, 50bp, and 8bp respectively.  
FENDRR KO Experiment 
The FENDRR KO experiment was conducted identical to the species mixing 
experiment with the following notable changes: Cells were loaded at a concentration 
of 50 cells/µL and beads were loaded at 120/µL. Sequencing was performed on the 
HiSeq 2500 in High Output mode. 
6) Bioinformatics Analysis 
Analysis pipeline for C1 
Raw reads were mapped using the Kallisto(84) pseudoalignment software to 
generate transcript counts. Transcripts mapping to ribosomal proteins were removed 
by selecting out transcript names beginning with Rpl and Rps. Subsequent analysis 
was performed with Bioconducter package ‘scater’(85). Multimapped transcripts 
mapping to the same gene were removed by keeping only the first instance of the 
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mapped transcript to avoid overrepresentation of specific genes. Only wells 
observed to contain single cells after initial the loading protocol were carried forward 
for further analysis. Low quality cells were then filtered out in order to eliminate cells 
with (1) total library size three median absolute deviations (MADs) below the median 
log-library size, cells in which the (2) log-transformed number of expressed genes is 
three MADs below the median, and (3) the proportion of transcript counts coming 
from mitochondrial genes greater than 10%. Subsequently, only features expressed 
in greater than 5 cells in each individual experiment were kept to eliminate noise 
generated from either imprecise mapping of low quality transcripts or low level 
stochastic expression. The union of the features remaining across each of the 
experimental groups was then combined, thus keeping only transcripts present in at 
least 5 cells in any of the experiments. Transcripts were then summarized at the 
gene level using the ‘summarizeExprsAcrossFeatures’ command which combines 
features using the observed transcripts per million. The expression levels were then 
normalized by using size factors computed by the ‘computeSumFactors’ command 
and setting the sizes of the pooling groups to ¼, ½, ¾ and 1x the total number of 
cells passing filtering. The normalized expression values were then fitted using 
LOESS regression and with Span=0.1 to estimate the biological and technical 
components of the variance of gene expression in each cell in an experiment. For 
unsupervised clustering, we selected a set of highly variable genes defined by those 
with biological variability significantly greater than zero at a specified FDR and 
biological variability threshold. A correlation matrix amongst these highly variable 
genes was constructed and an FDR threshold of 0.05 is used to select pairs of 
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correlated genes. The top 50 genes with the highest biological variability of this set 
of correlated genes was used to construct a dissimilarity matrix and hierarchical 
clustering was applied to create a heatmap. Potential clusters are identified using 
the package ‘dynamicTreeCut’(86) with a minimum cluster size of 10. For semi-
supervised clustering, an internally derived list of marker genes was developed. And 
hierarchical clustering was used to group cells according to this marker gene list with 
a minimum cluster size of 10.   
Analysis pipeline for Drop-Seq 
Demultiplexing was performed using the Drop-Seq tools software(87) following the 
standard parameters in the Drop-Seq Informatics Cookbook v1.2(88). Briefly, the 
following steps were taken to prepare the raw reads into a ‘cell x transcript’ count 
matrix. FASTQ files were converted into query-name sorted BAM files using 
Picard(89). Then cell barcodes were extracted as the first 12 base pairs of Read 1 
and transferred into metadata; a similar process extracted the next 8 UMI-encoding 
base pairs. Low quality reads were removed at this stage and primer sequences and 
polyA tails contaminating the reads were clipped away. The BAM file was converted 
back to a FASTQ file for alignment using STAR 2.5(90). The human and mouse 
genomes used in this analysis were the hg19 and mm10 reference genomes(91), 
respectively and the Ensembl release 87(92) genomic features files.  
The alignments were merged with unaligned metadata tagged BAM files to tag all 
the aligned reads with cell and UMI barcodes. Aligned reads were also tagged with a 
gene name metadata tag if the read occurred in the region of an annotated gene. 
Next, a bead synthesis quality detection program was run on the cell barcode and 
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UMI to detect any potential barcode or UMI redundancy issues associated with 
improper pool-and-split bead synthesis.  
The ‘knee-plot’ for cumulative reads was generated by plotting the cumulative sum 
of reads associated with each barcode, by descending order of number of reads per 
barcode. A cut-off was selected by inspecting the knee-plot for an inflection point 
were the number of reads per STAMP decreases significantly representing the zone 
of reads attributed to ambient RNA binding to beads. In the FENDRR KO 
experiment, 300 and 200 cells were used as the cut off for the S1 and F1 groups. 
For the species mixing experiment, 200 cell cutoff was used. These cells were 
designated STAMPs and were taken forward for creation of the DGE matrix. The 
DGE matrix data for the FENDRR experiment was further processed using the 
Bioconductor package ‘Seurat’(93). Cells with greater than 5% mitochondrial reads, 
fewer than 2000 detected genes, and UMIs greater than 10,000 were filtered out. 
For the T-SNE plots, we selected the top PCs (1-10) and a resolution parameter of 
0.6 to identify clusters. The ‘FindMarkers’ command was used to identify the marker 
genes for each cluster; the top 10 most highly expressed of this group of these 







1) Results of whole mouse lung experiments using the C1 
a. Quality control results of C1 analysis  
The overall capture rate for single cells for these experiments ranged from 44/96 
to 90/96 with an average of 72 single cells captured (Table 1). In order to improve 
the specificity of detection of important cell groups, low quality cells and features 
expressed at low levels in only small numbers of cells were filtered out. This process 
improves the ability of clustering algorithms to robustly group cells and not be 
swayed by noisy, lowly expressed genes or outlier cells with low quality. Filtering 
was first performed to eliminate cells in which (1) total library size three median 
absolute deviations (MADs) below the median log-library size, (2) the log- 
transformed number of expressed genes is three MADs below the median, and (3) 
the proportion of transcript counts coming from mitochondrial genes greater than 
10%. This process eliminates cells that deviate from the remainder of the pool in 
Table 1: Summary of read depth, single cell capture, and filtering steps. Results of 
quality filtering of whole lung samples on the C1 platform. Filtering criteria are described in 
depth in the text. Note that certain cells meet criteria for filtering and thus the sum of the 
filtered cells does not equal the total number of cells filtered.  
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terms of number of transcripts detected, diversity of transcripts detected, and the 
health of the cell based on the dominance of mitochondrial genes detected, 
respectively. In Figure 6, this process is shown in further detail. Under these filtering 
criteria, the final cell counts were extremely low for the doxycycline control at 26, and  
best for best for the Bleomycin treated mice.  
 Additional filtering was subsequently performed to remove lowly expressed 
transcripts that represent likely noise in the dataset. In our analysis, we removed 
transcripts that were not expressed in at least 5 cells. Transcript counts were 
Figure 6: Detailed view of filtering steps. 
A. Distribution of library sizes for the cells 
was approximately normally distributed and 
cells to the left of the line were filtered B. 
The median number of expressed genes 
was ~8000 and the four cells to the left of 
the filtering line were removed C. The vast 
majority of cells had <10% mitochondrial 
counts. Cells to the right of the line with 
high numbers of mitochondrial genes 
detected were presumed to be unhealthy 




aggregated at the gene level by summing over the transcripts per million of each 
transcript and then gene counts per cell were normalized. The post filtering 
distribution of the library size and the transcripts present (marked as ‘features’) in 
each cell are shown in Figure 7. The Tgfβ1 exposed mouse is distinct in that the 
cells all demonstrate a high diversity of transcripts and a tight distribution of the total 
transcripts detected.  
 
b. Assigning Cell Identity based on marker genes. 
A set of marker genes was developed internally for canonical genes used to 
categorize specific cell populations in the lung. Specifically, this list encompasses 
Type I Epithelial (AT1), Type 2 Epithelial (AT2), general alveolar epithelial, 
endothelial, pericyte, fibroblast, monocyte, and general mesenchymal stem cell 
lineage cells. These marker genes were then used to cluster each experimental 
Figure 7: Distribution of library sizes and feature counts. Violin plots are used 
here to show the distribution of the library sizes of each of the experimental groups. 
Each circle represents a cell, its position on the y-axis represents the log-normalized 
number of transcripts detected for that cell, and the color scale represents the 
number of unique transcripts detected.  
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treatment individually. Figure 8 shows the results of semi-supervised clustering for 
the Tgfβ1 data set based on this list of marker genes. The likely epithelial and 
mesenchymal lineages are indicated by the red horizontal bar and the combination 
of the purple, green, and cyan bars, respectively. There are several notable features 
of this data set. Under the purple cluster of cells are putative fibroblasts with higher 
expression of Col1a1 transcripts. A subset of these cells also expresses Acta2 and 
thus represents the myofibroblast subpopulation that is known to expand under 
fibrotic conditions. There is also a set of cells that expresses S100A4, which in 
humans is known as Fibroblast Specific Protein 1 (FSP-1) but does not express 
Col1a1 or Acta2. Finally, in the red cluster marked with high epithelial cell specific 
markers are a group of cells expressing Col1a1 and Acta2 at higher levels than the 
remainder of the cells.  
Figure 8: Semi-supervised clustering of  Tgfβ1 experiment based on marker 
genes. Clustering for Tgfβ1 mouse lung cells shows clear populations of cells 
expressing epithelial markers (red horizontal bar) and fibroblast markers (purple 












In figure 9, semi-supervised clustering for the Tgfβ1, Bleomycin, and 
combined control cells is shown. Generally the clustering bars along the top of the 
pooled control and bleomycin-treated mice also show separation along the epithelial-
mesenchymal axis. As expected, the number of cells showing fibroblast markers is 
most expanded in the bleomycin group in this data set, and is small and not strongly 












Figure 9: Semi-supervised clustering of 
all experiments based on marker 
genes. A, B, and C represent the 
aggregated control, the Tgfβ1, and the 
Bleomycin experiments, respectively. In all 
the data sets, there is a generally a 
separation of markers for the epithelial 
and mesenchymal lineages. Note that the 
horizontal bars at the top of each heatmap 
represent groups of cells detected by 
hierarchical clustering but the colors of the 
bars are arbitrary and furthermore to not 




c. Unbiased clustering of cell types 
 Cells were also analyzed using an unbiased clustering methodology. Similar 
to the semi-supervised clustering results, the Tgfβ1 experiment demonstrated the 
most robust clustering. Using a minimum cluster size of 10 cells, 6 clusters are 
identified with 4-5 gene modules. In figure 11, the top 50 most variable genes used 
in clustering are shown. The distribution of cells here is not representative of the 
normal lung environment(30). However, given the significant epithelial apoptosis and 
inflammatory infiltrate present in the characterization of this mouse(17), the 
distribution of cells is likely representative of the tissue environment in this mouse. 
Figure 10: Expression of fibroblast specific markers. Violin plots are used here to show in 
more detail the log-normalized differences in Acta2, Col1a1, and S100a4 between the treatment 
groups. Each point represents a cell, and each label on the x-axis denotes the sample that the 
cells shown in the plot above the label came from. Cells are colored based on the cluster they fall 
into using our unbiased clustering approach. Note, that the clustering colors are consistent within 











The same process performed on the aggregate control group and the 
bleomycin group does not cluster in a robust fashion nor do the clusters represent 
sets of genes with biologically discernable correlated expression.  
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Figure 11: Unsupervised clustering of Tgfβ1 experiment. Hierarchical clustering of the 
dissimilarity matrix between cells is presented here. Using a minimum cluster size of 10, six distinct 
clusters are identified. Inspection of the heatmap shows four to five sets of genes on which these 





















































































































































































































































































































































































2) Drop-seq analysis  
a. Species mixing experiment confirms viability of platform to generate valid single 
cell libraries 
The species mixing experiment was carried as described in the methods 
section. Initial experiments demonstrated excessive amplification of the post-PCR 
library (Figure 12). Subsequent libraries were prepared using the same set of beads 
and amplified using three fewer cycles. This resulted in properly amplified libraries 
similar to those in the DropSeq lab manual in Figure 12.B(88).  
In Figure 13, we demonstrate successful implementation of the Drop-Seq 
platform to create single cell libraries. In Libraries 1 and 2, 1.9% and 2% of the cells 
Figure 12: Amplification cycle determination for human-mouse experiment. Bioanalyzer 
provides the distribution of DNA size fragments found in a library. The x-axis represents the size of 
the fragment and the y-axis is a fluorescence measurement indicating the absolute abundance of 
fragments of the size indicated on the x-axis.  A. An overamplified library we generated using the 
13 cycles recommended in the Drop-Seq manual, this can be seen in comparison to B. which is 
reproduced from the Drop-Seq lab manual and is an ideal BioAnalyzer trace with an amplification 
peak near 200 FU and a peak fragment size near 1100bp representing the average size the 
reverse transcribed cDNA. We adjusted the cycle number to 10 and generated properly amplified 
libraries in C. D. with a peak near 100 FU at approximately 1100bp. 
200 
Over-amplified library Ideally amplified library 
200 





contained a mixed population of transcripts indicating a doublet. The estimated 
doublet rate in the system at this cell concentration of 100 cells/µL is 
approximately 4% if the probability of different doublet combinations is accounted 
for. Indeed some outlier cells with greater than 10,000 transcripts are seen in both 
libraries. It is highly likely that these are human-human doublets.  
Figure 13: Results of species mixing experiment. Replicates of the species mixing experiment 
demonstrating successful implementation of the Drop-Seq platform. Each dot represents a STAMP and 
are shaded blue or red if they contain greater than 95% of transcripts from human or mouse, 
respectively. A purple cell represents barcodes with both human and mouse cells.  
Species mixing Library 1 Species mixing Library 2 
Figure 15: Inflection plots of species mixing experiment. X-axis is the rank of the barcode (in 
descending order) by the number of reads that barcode has. Thus the barcode represented by ‘1’ 
has the most number of reads, ‘2’ has the second most, and so on. The number of reads 
associated with each barcode flattens out and this flattening represents the region of ambient 
barcodes. A. Library 1 demonstrates poor segregation of reads between STAMPs and barcodes 
bound to ambient RNA. B. Right plot is from the original Drop-Seq paper. A sharp inflection point 
is seen demonstrating a clear boundary between bona-fide single cell reads and reads from 































Rank of cell barcodes in descending order of reads/barcode 
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The inflection plots for the species mixing experiment (Figure 15) 
demonstrate low capture of STAMPs relative to ambient RNA. The Drop-Seq 
authors demonstrate 70% of their reads originate from STAMPs versus 17% for 
Library 1, and 15% for Library 2 (data not shown). Moreover, there is a sharp 
inflection point in the Drop-Seq author data (77) as compared to the soft inflection 
point seen in our results resulting from ambient RNA contamination causing 
attachment of RNA to beads that were not encapsulated with a cell after droplet 
breakage.  
No further analysis is performed on the species mixing experiment as the goal 
of this experiment is to provide system validation.  
b. FENDRR KO Library is a high quality library 
 The inflection plots for the FENDRR experiment (Figure 16) demonstrate 
there was significantly greater capture of true cells as a fraction of the total number 
of reads. This indicates less ambient RNA due to a higher quality cell suspension or 
more clean library preparation In these libraries, the inflection point occurs near at 
Figure 16: Inflection plots for FENDRR experiments.  A.  Inflection plot for the FENDRR 
incubated with scrambled, non-targeting RNA. B. FENDRR incubated with targeting siRNA 
inflection plot shows the sharpest inflection indicating the cleanest library preparation for this 
tissue and potentially as a result of greater resistance to apoptosis due to treatment.  




































Rank of cell barcodes in descending order of reads/barcode 
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200 cells for the control cells, and 300 cells for the FKO cells. After first pass filtering 
for low quality cells, not meeting a minimum expressed gene count of 2000 our data 
set consisted of 294, and 158 cells for the control and FKO groups. UMI counts are 
represented as a fraction of the total number of UMIs in the cell and multiplied by 
10,000 and log transformed.  
Further quality filtering steps were applied to this data set (Figure 17). In the 
total population of NHLFs the number of genes detected averages around 5,000 with 
the minimum number of genes expressed at 2,000 as set by the filter, and tapered 
off near 9,000. 10,000 mRNA bindings is an apparent maximum of the binding 
kinetics when one cell is encapsulated with one bead. A second cell entering a 
droplet shifts the kinetics towards greater binding of mRNAs. Thus STAMPs with 
over 10,000 UMIs were also filtered. STAMPs with greater than 5% mitochondrial 
reads were also filtered as these indicate cell releasing mitochondrial RNA indicative 
Figure 17: Quality 
filtering for NHLF 
FKO experiment. 
Read distributions of 
genes, UMIs, and 
mitochondrial reads. 
F1 represents the 
FENDRR KO cell and 
S3 represents the 
scrambled library. 
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of increased cellular stress. This is a more stringent threshold than the total lung 
experiment because the UMI counting enabled by the Drop-Seq experiment adjusts 
for the potential amplification bias of mitochondrial genes.  
c. FENDRR KO experiment confirms fibroblast changes seen in whole tissue 
experiments 
In order to confirm FENDRR knockdown in the FKO population, we looked 
specifically at FENDRR as well as ACTA2, the gene coding for SMA. In our lab, we 
validated that FENDRR knockdown increases the abundance of SMA (unpublished 
data) and thus focused on this change in analyzing the Drop-Seq results. In Figure 
18, FENDRR expression follows a bimodal distribution in both populations with a 
large number of samples showing no FENDRR expression. In the control population, 
this is likely due to dropout as FENDRR is expressed in relatively low numbers given 
Figure 18: ACTA2 and 
FENDRR expression in 
FKO and control cells.   
  
 FKO																Control FKO																Control 
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bead saturation kinetics, Drop-Seq has lower sensitivity for genes expressed at low 
levels. On average, FENDRR expression is decreased in the KO population. The 
cells still expressing FENDRR were likely due to inefficient transduction of FENDRR 
targeting-siRNA. ACTA2 is upregulated in the FKO population confirming the 
expected effect of treatment. There remains a population of cells that either do not 
express ACTA2, or express it levels similar to the control population.  
PCA analysis was performed on the combined group of filtered cells and 
genes to understand the spectrum and magnitude of changes induced by FENDRR 
KO (Figure 19). A first set of plots was generated using all the genes resulting in a 
moderate separation of the two groups of cells and a wide distribution of cells in the 
control group. A set of highly variable genes was selected in order to remove noisy 
Control 
FKO 
Figure 19: PCA plots of FENDRR KO experiment cells. 
A. PC1 vs PC2 for all genes. B. PCA analysis using only 
the top 100 for (left to right) PC1 vs PC2, PC1 vs PC3, and 




genes that skew creation of principal components. PCA plots generated for the first 
three PCs demonstrate improved clustering of the groups in terms of their separation 
and their intergroup variability although the control cells remain more widely 
distributed than the FKO cells.   
t-distributed stochastic neighbor embedding (T-SNE) based clustering was 
performed next as this dimensionality reduction technique is capable of accounting 
for non-linear relationships in the data(94, 95). We applied a T-SNE based clustering 
algorithm to this data set and three clusters were assigned. As seen in Figure 20, 
‘Cluster 3’ is almost completely composed of the FKO cells. Figure 21 shows the 
side by side expression of ACTA2 and FENDRR in on the T-SNE dimensions and 
shows the inverse relationship between the expression levels of these two genes 
further confirming that high expressing FENDRR cells correspond to lower levels of 
ACTA2 expression.  
Figure 20: T-SNE plot of FENDRR KO experiment. A. The T-SNE plot clustering algorithm 
determines three distinct clusters. B. Shows the same configuration of cells as clustered by the 






 In order to understanding the major drivers of the three clusters including the 
differences between ‘Cluster 0’ and ‘Cluster 1’ we selected the top 10 highly 
expressed genes in each cluster and created a heatmap (Figure 22). The top genes 
expressed in Cluster 1 are highly associated with G1 phase events (FDR = .0017) 
according to Reactome analysis(96, 97). Cluster 0 genes are not significantly 
associated with any process but are correlated with extracellular matrix formation 
and thus may correspond to features of normal fibroblast activity. Genes upregulated 
in ‘Cluster 3’, the cluster representing the FKO cells, are highly associated with a 
fibrotic phenotype including smooth muscle actin, a myofibroblastic protein(98), 
CDKN1A encoding p21 which has been found to be necessary for fibroblast entry 
into quiescence(99), and GDF15 has been show to regulate fibroblast 
Figure 21: ACTA2 and FENDRR expression in the T-SNE generated clusters. The inverse 
relationship between low FENDRR expression (low expression in gray) and high ACTA2 
expression (high expression in red), and vice versa, is more clearly shown on a cell specific 
basis.  
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activation(100) leading to increasing expression of smooth muscle actin in cancer 
associated fibroblasts and paradoxically in this scenario, proliferation(101). IGFBP5 




Figure 22: Heatmap divided by clusters generated by T-SNE analysis. The top 
differentially expressed genes in each cluster are shown in the heatmap revealing expected 
relationships due to FENDRR treatment and cell cycle status of the cells.  
 55 
Discussion 
We present here results from two single cell experiments. In one experiment, 
we used the C1 platform to investigate transcriptional changes between two models 
of pulmonary fibrosis –  Tgfβ1 overexpression and bleomycin lung injury. In the other 
experiment, we used Drop-Seq to determine the impact of siRNA mediated 
FENDRR knockdown. In the C1 experiment we harvested the whole lung of the 
mouse and generated a single cell suspension whereas in the Drop-Seq experiment, 
we used cultured normal human lung fibroblasts. Results were subsequently 
analyzed using unique data pipelines tailored to the specifics of the raw data output 
from each experiment.  Specifically, in Drop-Seq, cell barcodes and UMIs were 
assigned using one read of the paired-end reads, and the UMIs were used to 
normalize for asymmetric amplification due to amplification bias. The C1 experiment 
did not use this internal control, but full transcript matching was possible to enable 
isoform detection, however, we did not specifically analyze data at the isoform level. 
Data quality between C1 and Drop-Seq 
In considering the quality of the data between C1 and Drop-Seq the major 
parameters to consider include the percentage of cells passing threshold, absolute 
numbers of genes detected, mapping rates, and the biological plausibility of the 
clustering groups obtained.  
As it relates to cells passing thresholds, a greater number of cells were 
excluded using the C1 filtering steps but this varies depending on the specific 
experiment. Thus, the variability may be due more to sample preparation or inherent 
biological variability in the samples rather than technical differences in the protocol. 
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The Drop-Seq quality filtering pipeline also employs additional filters such as reads 
from mitochondrial cells that is not used in the C1 pipeline. Including these filters 
may result in additional cells being discarded. Finally, filtering for doublets or empty 
barcodes cannot be done in a definitive way using Drop-Seq and thus has to rely on 
surrogate measurements causing potentially inclusion of doublets or ‘empty droplets’ 
or exclusion of true single cell libraries.  
Rather surprisingly, the number of genes detected on both platforms after 
filtering was relatively similar averaging near 3000. This is interesting given that 
Drop-Seq requires significantly fewer amplification cycles than the C1. This raises 
the question of whether or not similar amplification cycles would result in fewer 
genes being detected on the C1. Moreover, we might expect a greater number of 
total genes to be detected on the C1 given that a total lung cell suspension should 
demonstrate a greater diversity of genes being expressed than a suspension from a 
single type of cell. The mapping rate on both platforms ranged from 60-80% and 
which is consistent with other single cell experiments.  
Subpopulations seen in whole mouse lung comparisons 
There are several interesting subpopulations that emerge on inspection of the 
supervised clustering results of the whole mouse lung. In the  Tgfβ1 data, there is 
evidence of EMT as cells that express epithelial markers are also shown to express 
markers of both Col1a1 and Acta2. There also exists a small subset of cells which 
expresses epithelial markers, and Col1a1 but not Acta2. This may be indicative of a 
continuum of differentiation in which cells transition to a final fate through 
intermediate stages. Another interesting population is the S100a4+ cells which do 
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not express any fibroblast markers, despite the fact that S100a4 is alternatively 
known as Fibroblast Specific Protein 1 or FSP-1. Other work has demonstrated that 
FSP-1 can also be present on inflammatory cells in human and experimental models 
of liver disease(103). As the Tgfβ1-overexpressing mice are known to exhibit 
significant inflammatory infiltrate at this stage of treatment, this subset of cells may 
correspond to the subpopulation of macrophages described in liver injury models. It 
is notable that Tgfβ1 transcripts were not directly detected in this analysis. This is 
likely due to the fact that the Tgfβ1 transcript that was expressed on the transgene in 
these mice is modified in multiple locations and thus the mapping algorithm fails to 
align the transcript reliably to the reference genome.   
Drop-Seq comparison of FENDRR KO vs. control NHLFs 
Single cell analysis of FENDRR KO confirms several findings from bulk 
analysis that are currently in publication by our group. Namely, we confirm on a 
single cell level that FENDRR ablation results in upregulation of SMA and 
senescence associated protein markers, namely p21. This modulation of p21 was 
found in our lab to occur via interaction with PRC2, a histone-modifying complex 
comprised of multiple proteins and whose functions is modular depending on the 
specific composition of the complex. This was confirmed based on enrichment of 
FENDRR RNA with RNA-IP to SUZ12 and EZH2, both components of the PRC2 
complex. In this analysis, we also found that several other lncRNAs demonstrated 
decreased expression relative to the control treated fibroblasts including Xist, 
Malat1, and Meg3. This may indicate a global effect on lncRNAs that occurs through 
FENDRR knockdown.  
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Single cell analysis also confirms previous studies on the incomplete 
efficiency of RNAi based knockdown of genes(104), and specifically of lncRNA. For 
lincRNA efficiency between 20-80% are typically noted, depending on the 
localization of the lncRNA as well as the mechanism of knockdown(105).  
Limitations and Future Work 
 There are several limitations that are important to highlight here. From a 
technical standpoint, there are limitations inherent to the tools used. For the C1 data, 
as previously described, there was no internal control to normalize the impact of 
amplification bias. For the Drop-Seq data, we assumed the isolation of single cells, 
however it is possible that cell doublets were being created in process of generating 
the droplets although this situation is unlikely. From a data analysis perspective, our 
ability to more completely analyze the C1 data was limited due the fact that the 
bleomycin experiment and the control experiments did not generate gene clusters 
with useful information. As such, we were not able to create comparisons of, for 
example, alveolar epithelial cells across the different models. Another important 
limitation of both platforms and experiments is the transcriptional impact of 
generating a single cell suspension. In the case of studying pulmonary fibrosis, the 
ECM and cell-ECM interactions have been shown to play a crucial role in 
understanding disease pathophysiology. The process of generating a single cell 
suspension, which involves mechanical digestion, as well as enzymatic digestion of 
the ECM components that attach cells to each other and the basement membrane, 
likely triggers important transcriptional changes. Moreover, there is likely a spectrum 
of vulnerability to cell rupture or apoptosis. This results in enrichment of the 
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healthiest or most apoptosis resistant cells and thus skews the potential cell 
populations seen. The process of flowing the cell suspension through the 
microfluidics of the device may also impart flow-dependent shear forces on the cells 
that can serve to alter a transcriptional profile. Finally, some portion of the reads in 
each cell in both experiments are due to ambient RNA which increases the technical 
noise present in the procedure.  
 In future work, implementation of some changes to the experimental workflow 
can lead in better data quality. For example, UMI barcodes have been incorporated  
to the C1 protocol(106), which may result in better clustering and thus analysis of the 
downstream data. From a methodological standpoint, to understand the impact of 
generation of a single cell solution a bulk tissue RNA-seq protocol should be used 
and the results should be compared to the single cell analysis in order to determine 
if there are major genes represented in cells that drop out due to preparation of the 
single cell suspension. Additional, the approximate abundances of the genes can be 
compared across the two analysis types to see determine if average representation 
of each gene remains constant. An important breakthrough in single cell genomic 
analysis will be the development of reagents that are able to ‘freeze’ the 
transcriptional state of the cell and simultaneously stabilize the cell membrane so 
that transcriptional changes and cell integrity and simultaneously preserved.  
 In summary, we have developed and validated two experimental protocols for 
measuring transcriptional changes in single cells from in vivo and in vitro models. 
These protocols will be used in future experiments with clinical samples of patients 
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